Eli Lilly and Company

Tularik Limited

Amgen Inc.

Protherics Medicines Development Limited

Stephen Clinton Young

Stuart Donald Jones

Christopher William Murray

John Walter Liebeschuetz

Michael Robert Wiley

William Alexander Wylie

Nicholas Paul Camp

John Joseph Masters

Brian Morgan Watson

Scott Martin Sheehan

David Birenbaum Engel

Phillip John Morgan

Andrew David Rimmer

Daniel Jon Sall

Peter Guzzo

Bohdan Waszkowycz

Jonathan Michael Ernest Roscoe

Pauline Mary Welsh

Michael John Mayer

Lawrence R McGee

Jolie Anne Bastian

Christopher Neil Farthing

Sarah Lively

Sharon McKendry

Philippe Bergeron

David Sheppard

Simon James Richards

Andrew Philip Austin Crew

James Francis Glover

Arthur Rushton

Steven Douglas Hiscock

Amanda Jane Lyons

Sarah E Lively

Stuart D Jones

Sharon Mckendry

Compounds of formula I in which R, R, R, each X, L, Y, Cy, Lp, D and n have the meanings as set out in the specification, and corresponding compounds in which the unsubstituted or substituted amidine group is replaced with an unsubstituted or substituted aminomethyl group, are useful as serine protease inhibitors.

Meta-benzamidine derivatives as serine protease inhibitors

Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR&#x3b3; or PPAR&#x3b4;. In particular, the compounds of the invention modulate the function of PPAR&#x3b3; or PPAR&#x3b4;. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.

Bisaryl-sulfonamides

Bisaryl-sulfonamide compounds having the formula wherein Ar, R, R, L, B, W, X, Y, and Z, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR&#x3b3; or PPAR&#x3b4;. In particular, the compounds of the invention modulate the function of PPAR&#x3b3; or PPAR&#x3b4;. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.

An angiotensin derivative comprising at least one angiotensin peptide moiety coupled to a peptide carrier-binding moiety which can be used for therapy and prophylaxis of conditions associated with the renin activated angiotensin system.

Angiotensin derivatives

Compounds of formula (I) in which R, X, Y, Cy, L and Lp(D)have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Serine protease inhibitors

Compounds of formula (I) in which R, R, R, n and Xhave the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.

Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders

Compounds of formula (I) in which R, R, Rand R, have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.

Chemical compounds

Compounds of formula (I)in which R, X, Y, Cy, L and Lp(D)have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

The compound 1-(indole-6-carbonyl-D-phenylglycinyl)-4-(1-methylpiperidin-4-yl)piperazine and physiologically-tolerable salts thereof are factor Xa inhibitors useful for the treatment of thrombotic disorders.

Compounds of formula (I)where R, each X, L, Y, Cy, Lp, D and n are as defined in the specification, are serine protease inhibitors useful as antithrombotic agents.

Growing community of inventors

Stockport, United Kingdom

Stephen Clinton Young